IL94128A - Nucleic acids encoding vascular endothelial cell growth factors, expression vectors and host cells comprising such nucleic acids and methods of producing such vascular endothelial growth factors - Google Patents

Nucleic acids encoding vascular endothelial cell growth factors, expression vectors and host cells comprising such nucleic acids and methods of producing such vascular endothelial growth factors

Info

Publication number
IL94128A
IL94128A IL9412890A IL9412890A IL94128A IL 94128 A IL94128 A IL 94128A IL 9412890 A IL9412890 A IL 9412890A IL 9412890 A IL9412890 A IL 9412890A IL 94128 A IL94128 A IL 94128A
Authority
IL
Israel
Prior art keywords
vascular endothelial
nucleic acids
growth factors
producing
methods
Prior art date
Application number
IL9412890A
Other languages
English (en)
Other versions
IL94128A0 (en
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL94128A0 publication Critical patent/IL94128A0/xx
Priority to IL15479703A priority Critical patent/IL154797A0/xx
Publication of IL94128A publication Critical patent/IL94128A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL9412890A 1989-05-12 1990-04-19 Nucleic acids encoding vascular endothelial cell growth factors, expression vectors and host cells comprising such nucleic acids and methods of producing such vascular endothelial growth factors IL94128A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL15479703A IL154797A0 (en) 1989-05-12 2003-03-06 Vascular endothelial cell growth factor that is unaccompanied by associated native glycosylation, pharmaceutical composition containing it and use thereof in the manufacture of a medicament for treating trauma affecting the vascular endothelium

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35111789A 1989-05-12 1989-05-12
US36942489A 1989-06-21 1989-06-21
US07/389,722 US5332671A (en) 1989-05-12 1989-08-04 Production of vascular endothelial cell growth factor and DNA encoding same

Publications (2)

Publication Number Publication Date
IL94128A0 IL94128A0 (en) 1991-01-31
IL94128A true IL94128A (en) 2005-11-20

Family

ID=27407983

Family Applications (2)

Application Number Title Priority Date Filing Date
IL9412890A IL94128A (en) 1989-05-12 1990-04-19 Nucleic acids encoding vascular endothelial cell growth factors, expression vectors and host cells comprising such nucleic acids and methods of producing such vascular endothelial growth factors
IL15479703A IL154797A0 (en) 1989-05-12 2003-03-06 Vascular endothelial cell growth factor that is unaccompanied by associated native glycosylation, pharmaceutical composition containing it and use thereof in the manufacture of a medicament for treating trauma affecting the vascular endothelium

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL15479703A IL154797A0 (en) 1989-05-12 2003-03-06 Vascular endothelial cell growth factor that is unaccompanied by associated native glycosylation, pharmaceutical composition containing it and use thereof in the manufacture of a medicament for treating trauma affecting the vascular endothelium

Country Status (14)

Country Link
US (2) US5332671A (de)
EP (1) EP0471754B1 (de)
JP (1) JP3117992B2 (de)
AT (1) ATE140968T1 (de)
AU (1) AU635935B2 (de)
CA (1) CA2054699C (de)
DE (1) DE69027990T2 (de)
DK (1) DK0471754T3 (de)
ES (1) ES2093025T3 (de)
IE (1) IE74169B1 (de)
IL (2) IL94128A (de)
NZ (1) NZ233451A (de)
PT (1) PT93996B (de)
WO (1) WO1990013649A1 (de)

Families Citing this family (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5240848A (en) * 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
EP0464155B1 (de) * 1989-03-24 1997-05-07 The Regents Of The University Of California Endothelialer zellwachsfaktor, isolierung und expression
US20030114374A1 (en) * 1989-05-12 2003-06-19 Genentech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
ZA903485B (en) * 1989-05-12 1992-01-29 Genentech Inc Production of vascular endothelial cell growth factor and dna encoding same
US7300791B2 (en) * 1989-05-12 2007-11-27 Genentech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
EP0399816B1 (de) * 1989-05-24 1995-12-20 Merck & Co. Inc. Reinigung und Charakterisierung eines von einem Glioma abstammenden Wachstumsfaktors
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US6083220A (en) 1990-03-13 2000-07-04 The Regents Of The University Of California Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas
USRE42625E1 (en) 1990-03-13 2011-08-16 The Regents Of The University Of California Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas
USRE42756E1 (en) 1990-03-13 2011-09-27 The Regents Of The University Of California Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas
EP0506477B1 (de) * 1991-03-28 1999-06-23 Merck & Co. Inc. Untereinheit-C des vaskulären endothelialen Zellwachstumsfaktors
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
EP0550296A3 (en) * 1991-11-28 1993-12-29 Terumo Corp Vascular endothelial cells growth factor
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
DE69233803D1 (de) * 1992-10-28 2011-03-31 Genentech Inc Verwendung von vaskulären Endothelwachstumsfaktor-Antagonisten
US5731294A (en) * 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
GB9402857D0 (en) 1994-02-15 1994-04-06 Isis Innovation Targeting gene therapy
US6152141A (en) * 1994-07-28 2000-11-28 Heartport, Inc. Method for delivery of therapeutic agents to the heart
WO1996006641A1 (en) * 1994-08-29 1996-03-07 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
US6130071A (en) * 1997-02-05 2000-10-10 Helsinki University Licensing, Ltd. Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
US6245530B1 (en) 1995-08-01 2001-06-12 Ludwig Institute For Cancer Research Receptor ligand
US6403088B1 (en) 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
US6221839B1 (en) * 1994-11-14 2001-04-24 Helsinki University Licensing Ltd. Oy FIt4 ligand and methods of use
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US6743779B1 (en) * 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
HU223438B1 (hu) * 1995-03-02 2004-07-28 Amrad Operations Pty. Ltd. Új növekedési faktor és ezt kódoló génszekvencia
US7160991B1 (en) 1995-03-02 2007-01-09 Ludwig Institute For Cancer Research Vascular endothelial growth factor polypeptides
DE69633121T2 (de) 1995-04-06 2005-07-28 Regeneron Pharmaceuticals, Inc. Tie-2 liganden, herstellungsverfahren und verwendung
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
WO1996039421A1 (en) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Human vascular endothelial growth factor 3
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7423125B2 (en) * 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US7005505B1 (en) 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
PT848755E (pt) 1995-09-08 2003-12-31 Genentech Inc Proteina relacionada com o vegf
US5830879A (en) 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
AU721034B2 (en) 1996-02-15 2000-06-22 Biosense, Inc. Catheter based surgery
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US7063965B2 (en) * 1996-04-05 2006-06-20 Regeneron Pharmaceuticals, Inc. Nucleic acid encoding TIE-2 ligand
WO1997040679A1 (en) * 1996-05-01 1997-11-06 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
ES2194203T3 (es) * 1996-06-19 2003-11-16 Regeneron Pharma Ligando del receptor tie-2 (ligando-4 de tie) y su uso.
US6846914B2 (en) * 1996-06-19 2005-01-25 Regeneron Pharmaceuticals, Inc. Tie-2 ligand-3
US6443974B1 (en) 1996-07-28 2002-09-03 Biosense, Inc. Electromagnetic cardiac biostimulation
EP0928203B1 (de) 1996-09-24 2006-10-25 Merck & Co., Inc. Verbindungen zur hemmung der angiogenese durch gentherapie
KR20000070572A (ko) 1997-01-29 2000-11-25 해우슬러 에이치 월터, 리처드 에스. 카훈 혈관형성 유도용 아데노바이러스 벡터의 다중 부위 운반
US7125714B2 (en) * 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US6395707B1 (en) 1997-02-14 2002-05-28 Genentech, Inc. Methods of treatment utilizing variants of vascular endothelial cell growth factor
US6485942B1 (en) 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
AU742365B2 (en) 1997-03-14 2002-01-03 Selective Genetics, Inc. Adenoviral vectors with modified tropism
DK1695985T3 (da) 1997-04-07 2011-06-14 Genentech Inc Fremgangsmåde til dannelse af humaniserede antistoffer ved tilfældig mutagenese
US6031155A (en) * 1997-06-05 2000-02-29 Cameron-Mills; Verena Arabinoxylan degradation
ATE371727T1 (de) 1997-06-18 2007-09-15 Merck & Co Inc Kdr, ein menschlicher tyrosin kinase rezeptor
US6391311B1 (en) 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
US20030129750A1 (en) * 1998-02-05 2003-07-10 Yitzhack Schwartz Homing of donor cells to a target zone in tissue using active therapeutics or substances
ES2255155T3 (es) 1998-02-05 2006-06-16 Biosense Webster, Inc. Dispositivo para la administracion intracardiaca de farmacos.
US20030113303A1 (en) * 1998-02-05 2003-06-19 Yitzhack Schwartz Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances
JP2002502608A (ja) 1998-02-06 2002-01-29 コラテラル・セラピューティックス・インコーポレイテッド 血管新生促進因子である血管内皮細胞成長因子：ｖｅｇｆの変異体
US6479729B1 (en) 1998-02-06 2002-11-12 The Johns Hopkins University Mouse model for ocular neovascularization
US6676937B1 (en) * 1998-03-09 2004-01-13 Caritas St. Elizabeth's Medical Center Of Boston Inc. Compositions and methods for modulating vascularization
US20040228834A1 (en) * 1998-03-09 2004-11-18 Jeffrey Isner Compositions and methods for modulating vascularization
EP2050762A3 (de) 1998-03-10 2009-07-08 Genentech, Inc. Neue Polypeptide und für diese kodierende Nukleinsäuren
AU758353B2 (en) * 1998-03-17 2003-03-20 Genentech Inc. Polypeptides homologous to VEGF and BMP1
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US7030083B2 (en) * 1998-09-09 2006-04-18 University Of Washington Treatment of eclampsia and preeclampsia
US6677300B1 (en) * 1998-09-09 2004-01-13 Scios, Inc. Treatment of microvascular angiopathies
CA2340320C (en) * 1998-09-09 2006-11-14 Scios Inc. Use of an angiogenic factor for the treatment of microascular angiopathies
EP1447089A3 (de) * 1998-09-09 2004-12-15 Scios Inc. Methoden zur Behandlung von Hypertonie und Zusammensetzungen dafür
EP1417971A3 (de) * 1998-09-09 2004-06-30 Scios Inc. Verwendung eines angiogenen Faktors zur Behandlung von mikrovaskulären Angiopathien
EP2016953A3 (de) 1998-12-22 2009-04-15 Genentech, Inc. Vaskuläre endotheliale Zellwachstumsfaktor-Antagonisten und Verwendungen
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
AU2878200A (en) 1999-02-11 2000-08-29 Schepens Eye Research Institute, Inc., The Growth medium for human corneal endothelial cells
EP1161451A4 (de) 1999-02-26 2006-05-17 Human Genome Sciences Inc Menschliches alpha-endokin und verfahren zu seiner verwendung
US7090834B1 (en) 1999-04-16 2006-08-15 Genentech, Inc. Vascular endothelial cell growth factor variants and uses thereof
CA2372053C (en) 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
US6475796B1 (en) 1999-05-20 2002-11-05 Scios, Inc. Vascular endothelial growth factor variants
AU5026100A (en) * 1999-05-20 2000-12-12 Scios Inc. Vascular endothelial growth factor dimers
WO2000078358A2 (en) * 1999-06-18 2000-12-28 The Collaborative Group, Ltd. Hyaluronic acid microspheres for sustained gene transfer
US7101706B1 (en) * 1999-06-25 2006-09-05 Insight Biopharmaceuticals Ltd. Polynucleotides and polypeptides encoded thereby distantly homologous to heparanase
DE19940012A1 (de) * 1999-08-24 2001-03-08 Karin Faerber Neues Mittel aus mindestens zwei Komponenten, das zum einen Gefäßneubildung (Neoangiogense) induziert des weiteren jedoch auch Gefäßverschlüsse (Restenosen) verhindert, das Verfahren seiner Herstellung und seine Verwendung
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
ATE526981T1 (de) * 2000-04-12 2011-10-15 Vib Vzw Verwendung von vegf 165 und homologen zur behandlung von neurologischen störungen
EP2792747A1 (de) 2000-06-23 2014-10-22 Genentech, Inc. Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
EP2168980A1 (de) 2000-06-23 2010-03-31 Genentech, Inc. Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
KR100419972B1 (ko) * 2000-09-09 2004-03-03 굿젠 주식회사 링커 염기서열로 연결된 인간 ｖｅｇｆ의 돌연변이형동형이합체 유전자, 이를 포함하는 발현벡터, 이의형질전환체 및 단백질
US6506365B1 (en) 2000-09-25 2003-01-14 Baxter Aktiengesellschaft Fibrin/fibrinogen binding conjugate
US7067317B2 (en) * 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7026462B2 (en) * 2000-12-07 2006-04-11 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
DK1414471T3 (da) 2001-07-17 2012-07-16 Res Dev Foundation Terapeutiske midler omfattende pro-apoptotiske proteiner
NZ530985A (en) 2001-08-29 2006-03-31 Genentech Inc Bv8 nucleic acids and polypeptides with mitogenic activity
AU2002328200B2 (en) * 2001-09-27 2008-01-03 Bionomics Limited DNA sequences for human angiogenesis genes
NZ531570A (en) * 2001-09-27 2006-03-31 Bionomics Ltd DNA sequences for human angiogenesis genes
US6953241B2 (en) 2001-11-30 2005-10-11 Brother Kogyo Kabushiki Kaisha Ink-jet head having passage unit and actuator units attached to the passage unit, and ink-jet printer having the ink-jet head
US20030171556A1 (en) * 2001-12-13 2003-09-11 Chi-Bom Chae Beta-amyloid binding factors and inhibitors thereof
US7795213B2 (en) * 2001-12-13 2010-09-14 Posco Methods of contacting β amyloid protein with VEGF
ES2500918T3 (es) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Proteínas de fusión de albúmina e interferón beta
US7081443B2 (en) 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
US7335362B2 (en) * 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
BRPI0312818B8 (pt) * 2002-07-19 2021-05-25 Beth Israel Deaconess Medical Ct Inc uso de uma medida do nível do polipeptídeo sflt-1 em uma amostra de uma paciente e uso de uma medida dos níveis de pelo menos dois dos peptídeos sflt1, vegf livre ou polipeptídio pigf livre em uma amostra de um paciente usando um métrico
US7435419B2 (en) * 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
US20060057694A1 (en) * 2003-01-29 2006-03-16 Thomas Kenneth A Jr Rat receptor tyrosine knase, kdr
CN102225194B (zh) 2003-03-12 2014-07-16 健泰科生物技术公司 Bv8和/或EG-VEGF促进造血的用途
WO2005014619A2 (en) 2003-03-28 2005-02-17 Thomas Jefferson University Heparin-binding peptides and uses thereof
US7601341B2 (en) 2003-06-05 2009-10-13 Research Development Foundation Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis
AU2005244167A1 (en) * 2004-05-04 2005-11-24 Beth Israel Deaconess Medical Center Methods and compositions for treatment of preeclampsia
DE602005023155D1 (de) 2004-05-27 2010-10-07 Life Sciences Res Partners Vzw Behandlung von amyotrohper lateralsklerose
AU2005273968A1 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
AR050608A1 (es) * 2004-08-19 2006-11-08 Alza Corp Aparato y metodo para administracion transdermica de factores de crecimiento endotelial vascular
US20060067937A1 (en) * 2004-09-24 2006-03-30 Karumanchi S A Methods of diagnosing and treating complications of pregnancy
US7740849B2 (en) * 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
US7691365B2 (en) 2004-09-28 2010-04-06 Aprogen, Inc. Methods of using chimeric coiled coil molecule to treat ischemic disease
DE602005023216D1 (de) * 2004-12-15 2010-10-07 Beth Israel Hospital Nukleinsäuren und polypeptide zur diagnose und behandlung von schwangerschaftskomplikationen
US7358085B2 (en) 2005-02-28 2008-04-15 Sangamo Biosciences, Inc. Anti-angiogenic methods and compositions
EP1877065A4 (de) * 2005-04-12 2010-12-22 Intradigm Corp Zusammensetzung und verfahren mit rnai-therapeutika zur behandlung von krebs und anderen gefässneubildungserkrankungen
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
EP1904094A2 (de) * 2005-06-17 2008-04-02 Genentech, Inc. Verwendung von vegf zur wundheilung
ES2363758T3 (es) 2005-08-15 2011-08-16 Vegenics Pty Ltd Vegf y pdgf modificados con propiedades angiogénicas mejoradas.
US8329175B2 (en) * 2005-08-26 2012-12-11 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the treatment and diagnosis of endothelial cell disorders and angiogenic disorders
MY143274A (en) * 2005-12-22 2011-04-15 Genentech Inc Recombinant production of heparin binding proteins
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
TWI476207B (zh) 2006-07-14 2015-03-11 Genentech Inc 重組蛋白之再摺疊
WO2008080052A1 (en) * 2006-12-22 2008-07-03 Genentech, Inc. Transgenic mice expressing humanized vegf
EP2139447A2 (de) 2007-03-20 2010-01-06 Harold Brem Gm-csf-kosmezeutikazusammensetzungen und verfahren zu ihrer verwendung
WO2008116111A2 (en) * 2007-03-20 2008-09-25 Harold Brem Growth factor mediated cosmeceuticals and use thereof to enhance skin quality
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
CN101932333A (zh) 2007-12-26 2010-12-29 瓦西尼斯公司 抗c35抗体联合疗法和方法
ES2642159T3 (es) * 2008-01-18 2017-11-15 Natco Pharma Limited Proceso para la preparación de derivados de 6,7-dialcoxi-quinazolina
EP2310507A4 (de) 2008-07-08 2013-03-20 David Gladstone Inst Verfahren und zusammensetzungen zur angiogenesemodulierung
US9050341B2 (en) * 2009-07-14 2015-06-09 Natco Pharma Limited Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
JP5959506B2 (ja) 2010-05-14 2016-08-02 ベス イスラエル デアコネス メディカル センター インコーポレイテッド 妊娠合併症を治療するための体外デバイスおよび方法
EP2600901B1 (de) 2010-08-06 2019-03-27 ModernaTX, Inc. Pharmazeutische zusammensetzungen enthaltenbearbeitete nukleinsäuren und ihre medizinische verwendung
HRP20220796T1 (hr) 2010-10-01 2022-10-14 ModernaTX, Inc. Ribonukleinske kiseline koje sadrže n1-metil-pseudouracil i njihove uporabe
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3492109B1 (de) 2011-10-03 2020-03-04 ModernaTX, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
RS63244B1 (sr) 2011-12-16 2022-06-30 Modernatx Inc Kompozicije modifikovane mrna
US20130165504A1 (en) * 2011-12-21 2013-06-27 modeRNA Therapeutics Methods of increasing the viability or longevity of an organ or organ explant
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
AU2014231770B2 (en) 2013-03-13 2020-01-30 The University Of Queensland A method of isolating cells for therapy and prophylaxis
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
RS62672B1 (sr) 2015-04-03 2021-12-31 Univ Massachusetts Oligonukleotidna jedinjenja za tretman preeklampsije i drugih angiogenskih poremećaja
EP3334499A4 (de) 2015-08-14 2019-04-17 University of Massachusetts Bioaktive konjugaten zur freisetzung von oligonukleotiden
EP3337820B1 (de) 2015-08-17 2020-10-14 Lupin Limited Verbessertes rückfaltungsverfahren für fragmente eines antikörpers
CA3011894A1 (en) 2016-01-31 2017-08-03 University Of Massachusetts Branched oligonucleotides
CA3033368A1 (en) 2016-08-12 2018-02-15 University Of Massachusetts Conjugated oligonucleotides
EP3642341A4 (de) 2017-06-23 2021-06-16 University Of Massachusetts Zweiendige selbstfreisetzende sirna und verwandte verfahren
JP2021533762A (ja) 2018-08-10 2021-12-09 ユニバーシティ・オブ・マサチューセッツUniversity Of Massachusetts Ｓｎｐを標的化する修飾オリゴヌクレオチド
EP4010476A4 (de) 2019-08-09 2023-12-27 University Of Massachusetts Gegen snps gerichtete chemisch modifizierte oligonukleotide
AR126207A1 (es) 2021-06-23 2023-09-27 Univ Massachusetts Compuestos de oligonucleotidos anti-flt1 optimizados para el tratamiento de la preeclampsia y otros desordenes angiogénicos
WO2023172964A2 (en) * 2022-03-08 2023-09-14 Yale University Vegf-c muteins for selective lymphatic stimulation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US456550A (en) * 1891-07-28 Shuttle-box-operating mechanism for looms
US4456550A (en) * 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
US4863899A (en) * 1983-05-09 1989-09-05 Todaro George J Biologically active polypeptides
US4444760A (en) * 1983-06-17 1984-04-24 Merck & Co., Inc. Purification and characterization of a protein fibroblast growth factor
US4721672A (en) * 1985-08-28 1988-01-26 President And Fellows Of Harvard College CDNA and gene for human angiogenin (angiogenesis factor) and methods of expression
US5073492A (en) * 1987-01-09 1991-12-17 The Johns Hopkins University Synergistic composition for endothelial cell growth
US5008196A (en) * 1987-08-21 1991-04-16 Monsanto Company Stimulation of endothelial cell growth
US5240848A (en) * 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5227302A (en) * 1988-12-20 1993-07-13 Ludwig Institute For Cancer Research DNA encoding platelet derived endothelial cell growth factor (PD-ECGF)
US6899882B1 (en) * 1989-03-24 2005-05-31 The Regents Of The University Of California Endothelial cell growth factor methods of isolation and expression
EP0464155B1 (de) * 1989-03-24 1997-05-07 The Regents Of The University Of California Endothelialer zellwachsfaktor, isolierung und expression
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US20030114374A1 (en) * 1989-05-12 2003-06-19 Genentech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
ZA903485B (en) * 1989-05-12 1992-01-29 Genentech Inc Production of vascular endothelial cell growth factor and dna encoding same
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5219739A (en) * 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121

Also Published As

Publication number Publication date
IL154797A0 (en) 2003-10-31
DK0471754T3 (da) 1996-11-04
IE901494L (en) 1990-11-12
CA2054699A1 (en) 1990-11-13
IE74169B1 (en) 1997-07-02
DE69027990D1 (de) 1996-09-05
DE69027990T2 (de) 1997-01-30
JP3117992B2 (ja) 2000-12-18
AU635935B2 (en) 1993-04-08
IL94128A0 (en) 1991-01-31
CA2054699C (en) 2002-07-02
EP0471754B1 (de) 1996-07-31
US20070161558A1 (en) 2007-07-12
AU5657490A (en) 1990-11-29
ATE140968T1 (de) 1996-08-15
PT93996A (pt) 1991-01-08
EP0471754A1 (de) 1992-02-26
WO1990013649A1 (en) 1990-11-15
ES2093025T3 (es) 1996-12-16
NZ233451A (en) 1992-10-28
US5332671A (en) 1994-07-26
JPH04505705A (ja) 1992-10-08
PT93996B (pt) 1997-09-30

Similar Documents

Publication Publication Date Title
IL94128A (en) Nucleic acids encoding vascular endothelial cell growth factors, expression vectors and host cells comprising such nucleic acids and methods of producing such vascular endothelial growth factors
IE883612L (en) Vectors and compounds for direct expression of activated human protein c
LU90855I2 (en) Proteine 1 osteogenique recombinante humaine: bmp-7 et ses d-riv-s pharmaceutiquement acceptables
GB2197324B (en) Process for the production of a polypeptide
NZ219485A (en) Production of human endothelial cell growth factor comprising transforming a host cell with an expression vector
ES8600783A1 (es) Procedimiento para la preparacion de la hormona polipeptidica factor de crecimiento de nervios de humano.
ATE121781T1 (de) Verwendung von dns-fragmenten, die ein signalpeptid kodieren zur sekretion von reifen proteinen in rekombinanten hefen, expressions- kassetten, transformierte hefen und verfahren zur herstellung dieser proteine.
ES8802159A1 (es) Un procedimiento de producir un acido desoxirribonucleico (adn)que tiene o contiene una secuencia de base que codificaun polipeptido de factor de necrosis tumoral de humano
AU682140B2 (en) Multidrug resistance gene
HK206196A (en) Acid-labile subunit (ALS) of insulin-like-growth factor (IGF) binding protein complex
KR880009991A (ko) 항혈액응고작용을 갖는 폴리펩티드
CA2006969A1 (en) Polypeptide having human monocyte chemotactic factor activity and a dna encoding said polypeptide
ATE194624T1 (de) Mutanten von menschlichem antithrombin iii
IL90947A (en) Method for production of hiv protease in transformed cells, dna and vectors comprising said dna used in said production
AU2430588A (en) Mutant acidic fibroblast growth factor
EP0387355A4 (en) Luciferase, luciferase-coding gene, and process for preparing luciferase
EP0315118A3 (de) Endothelin kodierendes DNA und dessen Verwendung
JPS6427473A (en) Human pancreas-secreting trypsin inhibitor and production thereof
ES8605296A1 (es) Procedimiento de producir factor viii-r humano
ATE116366T1 (de) Verfahren zur herstellung eines menschlichen ''neutrophil chemotactic factor''-polypeptids.
DE3882455D1 (de) Verfahren zur herstellung von proteinen in loeslicher form.
ES2111537T3 (es) Inhibidor de la ribonucleasa de placenta humana recombinante y metodo de produccion.
RU96124779A (ru) Днк, кодирующая кератиназу bacilus licheniformis pwd-1
ATE93893T1 (de) Expressionssysteme zur ueberproduktion gewuenschter proteine.
MX9700255A (es) Metodo para identificar acidos nucleicos que codifican las proteinas activadoras del promotor c-fos.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
EXP Patent expired